Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies.


Dominique Rosillon, GSK, Wavre, BelgiumFollow
Laurence Baril, GSK, Wavre, Belgium
Maria Rowena Del Rosario-Raymundo, Department of Obstetrics and Gynecology, San Pablo Colleges Medical Center, San Pablo City, The Philippines
Cosette Marie Wheeler, University of New Mexico Health Sciences Center, Albuquerque, New Mexico
Susan Rachel Skinner, Vaccines Trials Group, Telethon Kids Institute, Perth, Western Australia, Australia. Sydney University Discipline of Paediatrics and Child Health, Children's Hospital Westmead, Sydney, New South Wales, Australia
Suzanne Marie Garland, The Royal Women's Hospital, The Royal Children's Hospital, Murdoch Childrens Research Institute, University of Melbourne, Parkville, Victoria, Australia
Jorge Salmeron, Instituto Mexicano del Seguro Social, Morelos, Mexico
Eduardo Lazcano-Ponce, National Institute of Public Health, Cuernavaca, Mexico
Carlos Santiago Vallejos, Departamento de Oncología Médica, Oncosalud-AUNA, Lima, Peru
Tanya Stoney, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia
Bram Ter Harmsel, Department of Gynecology, Roosevelt Kliniek, Leiden, Delft, The Netherlands
Timothy Yong Kuei Lim, KK Hospital, Singapore City, Singapore
Swee Chong Quek, ASC Clinic for Women, Gleneagles Hospital, Singapore City, Singapore
Galina Minkina, City Clinical Hospital, Moscow, Russia
Shelly Ann McNeil, Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia, Canada
Celine Bouchard, Clinique de Recherche en Santé des Femmes, Québec City, Québec, Canada
Kah Leng Fong, Singapore General Hospital, Singapore City, Singapore
Deborah Money, The Women's Health Research Institute, University of British Columbia, Vancouver, British Columbia, Canada
Arunachalam Ilancheran, Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, National University Hospital, Singapore City, Singapore
Alevtina Savicheva, Laboratory of Microbiology, DO Ott Research Institute of Obstetrics, Gynaecology and Reproductology, St. Petersburg, Russia
Margaret Cruickshank, Department of Obstetrics and Gynaecology, Aberdeen Maternity Hospital, NHS Grampian, Scotland, UK
Archana Chatterjee, Department of Pediatrics, University of South Dakota Sanford School of Medicine/Sanford Children's Specialty Clinic, Sioux Falls, South Dakota
Alison Fiander, Leading Safe Choices Programme, Royal College of Obstetricians and Gynaecologists, London, UK
Mark Martens, Reading Hospital-Tower Health, Reading, PA
Marie Cecile Bozonnat, 4Clinics, Paris, France
Frank Struyf, GSK, Wavre, Belgium
Gary Dubin, GSK, King of Prussia, Pennsylvania
Xavier Castellsagué, Institut Català d'Oncologia (ICO), IDIBELL, CIBER-ESP, L'Hospitalet de Llobregat, Catalonia, Spain

Document Type


Publication Date



BACKGROUND: Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the degree of protection from naturally acquired anti-HPV antibodies is uncertain. We examined the risk of HPV infections as defined by HPV DNA detection and cervical abnormalities among women >25 years in the Human Papilloma VIrus Vaccine Immunogenicity ANd Efficacy trial's (VIVIANE, NCT00294047) control arm.

METHODS: Serum anti-HPV-16/18 antibodies were determined at baseline and every 12 months in baseline DNA-negative women (N = 2687 for HPV-16 and 2705 for HPV-18) by enzyme-linked immunosorbent assay (ELISA) from blood samples. HPV infections were identified by polymerase chain reaction (PCR) every 6-months, and cervical abnormalities were confirmed by cytology every 12 months. Data were collected over a 7-year period. The association between the risk of type-specific infection and cervical abnormalities and serostatus was assessed using Cox proportional hazard models.

RESULTS: Risk of newly detected HPV-16-associated 6-month persistent infections (PI) (hazard ratio [HR] = 0.56 [95%CI:0.32; 0.99]) and atypical squamous cells of undetermined significance (ASC-US+) (HR = 0.28 [0.12; 0.67]) were significantly lower in baseline seropositive vs baseline seronegative women. HPV-16-associated incident infections (HR = 0.81 [0.56; 1.16]) and 12-month PI (HR = 0.53 [0.24; 1.16]) showed the same trend. A similar trend of lower risk was observed in HPV-18-seropositive vs -seronegative women (HR = 0.95 [0.59; 1.51] for IIs, HR = 0.43 [0.16; 1.13] for 6-month PIs, HR = 0.31 [0.07; 1.36] for 12-month PIs, and HR = 0.61 [0.23; 1.61] for ASC-US+).

CONCLUSIONS: Naturally acquired anti-HPV-16 antibodies were associated with a decreased risk of subsequent infection and cervical abnormalities in women >25 years. This possible protection was lower than that previously reported in 15- to 25-year-old women.

Publication Title

Cancer Med





First Page


Last Page


This document is currently not available here.